NCT03774615终止4 期
A Phase IV Study to Explore the Safety of ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency in Patients With Heart Failure Carrying Left Ventricular Assist Devices (ORION-LVAD-1)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- To detect AEs and SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric maltol for 12 weeks
研究概览
简要总结
This is a open-label, uncontrolled, monocenter, phase IV study. The aim of this study is to detect AEs or SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric maltol for 12 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent prior to any study-related procedure and willingness to comply with treatment and follow-up procedures
- •Male and female patients ≥18 years at day of inclusion
- •Patients capable of understanding the investigational nature, potential risks and benefits of the clinical trial
- •Patients that have an LVAD implanted for chronic heart failure and which are clinically stable for at least 6 months after LVAD implantation in the opinion of the investigator
- •6 min walk distance >50 m
- •Mild-to-moderate iron-deficiency anemia as defined by a hemoglobin concentration ≥7 g/dl and <12 g/dl in females or ≥8 g/dl and <13 g/dl in males, and serum ferritin <100 µg/l, or 100-300 µg/l and transferrin saturation <20% at screening
- •Women of childbearing potential must:
- •Have a negative pregnancy test at screening Agree to use reliable methods of contraception during the course of the study
排除标准
- •Active hematological disorders other than iron-deficiency anemia
- •Other medical condition that according to the investigator's assessment is causing or contributing to anemia
- •Active malignancy
- •Active infectious disease
- •Active bleeding
- •Severe renal insufficiency (requiring dialysis)
- •Severe liver injury as indicated by serum aminotransferases >3 x upper limit of normal or bilirubin levels >50 µmol/l
- •Ongoing oral or intravenous iron supplementation
- •Concomitant erythropoietin medication
- •Pregnancy or lactation period
- •Subject has received any investigational medication or any investigational devices within 30 days prior to the first dose of study medication or is actively participating in any investigational drug/ devices trial, or is scheduled to receive investigational drug/devices during the course of the study.
- •Known or suspected hypersensitivity to any of the active substances or any excipients of the investigational medicinal product
- •Known haemochromatosis or other iron overload syndromes
- •Patients who have been receiving repeated (>1) blood transfusions during the past 6 months
研究组 & 干预措施
Ferric maltol 30 mg (Feraccru®)
Experimental
Treatment with Feraccru® 30 mg hard capsules (Ferric maltol 30 mg). One capsule twice daily, morning and evening, on an empty stomach for 12 weeks
干预措施: Ferric maltol 30 mg (Feraccru®) (Drug)
结局指标
主要结局
To detect AEs and SAEs with a relative frequency of at least 11.5% in LVAD patients with iron deficiency anemia treated with oral ferric maltol for 12 weeks
时间窗: baseline to week 12
次要结局
- Change in NYHA from baseline to week 12(from baseline to week 12)
- Change in serum ferritin levels and transferrin saturation from baseline to week 6(baseline to week 6)
- Change in echocardiographic markers of left ventricular function (left ventricular ejection fraction, left atrial area, left ventricular diameter, fractional area change, tricuspid annular plane systolic excursion)(change from baseline to week 12)
- Change in hemoglobin level from baseline to week 12(baseline to week 12)
- Change in 6 min walking distance from baseline to week 12(baseline to week 12)
- Kidney: Change in Creatinine (+GFR) and Urea from baseline to week 12(from baseline to week 12)
- Change in hemoglobin level from baseline to week 6(baseline to week 6)
- Change in serum ferritin levels and transferrin saturation from baseline to week 12(baseline to week 12)
- Liver: Change in Albumin, ALT, AST and Bilirubin from baseline to week 12(from baseline to week 12)
- Liver: Change in Albumin, ALT, AST and Bilirubin from baseline to week 6(from baseline to week 6)
- Change in serum NT-proBNP from baseline to weeks 6(baseline to weeks 6)
- Change in serum NT-proBNP from baseline to weeks 12(baseline to weeks 12)
- Change in echocardiographic markers of right ventricular function (right atrial area, right ventricular diameter, fractional area change, tricuspid annular plane systolic excursion)(change from baseline to week 12)
- Kidney: Change in Creatinine (+GFR) and Urea from baseline to week 6(from baseline to week 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of AgeHIVNCT01335620Imperial College London19
已完成
4 期
Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).Metastatic Colorectal CancerNCT03564938Bayer100
已完成
4 期
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese SubjectsCardiovascular DiseaseNCT02705807GlaxoSmithKline10
进行中（未招募）
1 期
Safety and Efficacy Study of NGGT002 in PKU Adult SubjectsPhenylketonuriasNCT06061614The First Affiliated Hospital of Bengbu Medical University15
已完成
4 期
Efficacy and Safety of Ikervis Under Controlled Environmental Conditions EnvironmentDry Eye SyndromesSevere KeratitisDry EyeNCT04492878Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA25